-
Clinical Research News | cAMPfield is launching a global phase 2b trial for moderate-to-severe ulcerative colitis and a global phase 2 for Crohn’s disease; Gero intends to advance a portfolio of both disease-modifying and aging-slowing programs in parallel; ClearNote Health continues commercial clinical study execution and broader global access; and more. more...
July 01, 2026
-
Clinical Research News | The Ellison Medical Institute enters an exclusive license with UniQuest; TrialAssure and Cancer Research UK’s Centre for Drug Development announce new partnership; EndoDNA launches BIOS, a clinical decision-support; and more. more...
June 30, 2026
-
Clinical Research News | India has long been called the pharmacy of the world. That reputation was earned through manufacturing scale, generics leadership, and the ability to supply medicines globally at extraordinary volume. But the next chapter for India’s pharmaceutical industry will be different. Recent industry discussion about India’s pharmaceutical ambitions has largely explored one question: Can India compete with China as a global pharmaceutical power? more...
June 26, 2026
-
Clinical Research News | In mid-June Novo Nordisk announced, “an IT security incident involving unauthorized access to a limited number of internal IT systems” that exposed personal information for clinical trial participants. Novo Nordisk listed the exposed data categories as Patient ID (random alphanumeric string) and information on trial participation; sex; year of birth; biomarkers; health/immunogenicity data; and lifestyle factors including smoking, alcohol use, and BMI. more...
June 23, 2026
-
Clinical Research News | For years, TMF leaders advocated for active TMF, a model where the TMF is a "place to go to do your work" instead of a passive archive. The shift to active TMF made significant progress for life sciences, moving toward applications that deliver real-time trial execution and TMF management. With the introduction of agentic AI in clinical trials, TMF management is now evolving from active to autonomous. more...
June 18, 2026
-
Clinical Research News | At last month's Bio-IT World Conference & Expo, Douaa Mugahid, PhD, Data Officer at the Hi-IMPAcTB Consortium at the Harvard School of Public Health moderated a panel of academics, investors, and consultants to take on the future of public data and software infrastructure. It is time to safeguard publicly funded data infrastructure, which underpins virtually all of modern biomedical research. more...
June 17, 2026
-
Clinical Research News | For the roughly 1.3 to 2 million women who visit their doctor each year with abnormal postmenopausal bleeding, the diagnostic journey has long been an uncomfortable one. The standard workup typically involves an endometrial biopsy—an invasive, often painful procedure that, despite its widespread use, fails to yield a conclusive diagnosis in more than 30% of cases. Two veteran diagnostics executives think there's a better way, and they're betting nearly $45 million in venture funding on it. more...
June 16, 2026
-
Clinical Research News | A novel urine-based liquid biopsy developed at Stanford University is showing remarkable accuracy in predicting bladder cancer recurrence and may soon reshape how clinical trials enroll and treat patients. The test, developed by urologic oncologist Joseph Liao, M.D., and colleagues, filters out age-related background mutations in urine to produce a cleaner, more reliable signal for detecting residual cancer after surgery and immunotherapy. more...
June 11, 2026
-
Clinical Research News | In the latest episode of The Scope of Things, Eugene Manley, Jr., founder and CEO of the STEMM & Cancer Health Equity Foundation, explains how underrepresented populations, including Black, Hispanic, Indigenous, rural, low-income, immigrant, underinsured, and uninsured communities, are less likely to receive guideline-aligned biomarker testing and less likely to be asked about clinical trial participation at all. more...
June 09, 2026
-
Clinical Research News | The diagnostics industry is at the intersection of enormous clinical development and technological change, enabling first-ever detection milestones heavily driven by artificial intelligence and multi-biomarker tests. But it has increasingly been coming into conflict with a decades-old regulatory system that didn’t anticipate these technological changes and a political environment that favors U.S. competition and innovation but is also interested in cutting the budget. more...
June 04, 2026